Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Pfizer 15.034, CSL 3.6525.
* CSL reports semi-annually. Values are evenly split across both quarters within each half.
Pfizer vs CSL: Revenue Comparison
Pfizer (PFE) and CSL (CSL.AX) are peers in Vaccines. Pfizer reported revenue of $15.0B as of Q2 2026, compared with $7.3B for CSL. Pfizer leads on revenue.
Pfizer's gross margin is 72.8% versus 44.4% for CSL. Pfizer's net margin is -1.6% versus -40.2% for CSL.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Pfizer, CSL.| Metric | Pfizer | CSL |
|---|---|---|
| Market Cap | - | - |
| Revenue | $15.03B | $7.30B |
| Cost of Revenue | $4.09B | $4.06B |
| Gross Profit | $10.94B | $3.24B |
| Operating Income | $4.71B | $1.39B |
| Net Income | $-246.00M | $-2.94B |
| R&D Expense | $2.81B | $614.00M |
| Earnings Per Share | -$0.04 | -$6.14 |
| Gross Margin | 72.8% | 44.4% |
| Operating Margin | 31.3% | 19.0% |
| Net Profit Margin | -1.6% | -40.2% |
| Free Cash Flow | $302.00M | $1.76B |
| Cumulative Free Cash Flow | $356.70B | $21.56B |
| Operating Cash Flow | $835.00M | $2.09B |
| Cash & Equivalents | $976.00M | $1.51B |